lonafarnib has been researched along with tanespimycin in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (tanespimycin) | Trials (tanespimycin) | Recent Studies (post-2010) (tanespimycin) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 921 | 39 | 496 |
| Protein | Taxonomy | lonafarnib (IC50) | tanespimycin (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.004 | |
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 3 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 7.65 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.031 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.9391 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.5124 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 3 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.031 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.496 | |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | 0.78 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
1 other study(ies) available for lonafarnib and tanespimycin
| Article | Year |
|---|---|
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |